FCs and CAR Ts teamwork makes the dreamwork
DOI:
https://doi.org/10.17161/mjusc.v4i1.23981Palabras clave:
CAR T Cell Therapy, Dendritic cell vaccine, cancer, solid state tumorResumen
Chimeric antigen receptor (CAR) T-cell therapy has recently been a huge topic in cancer immunotherapy, however the effect on solid state tumors remains limited due to poor tumor infiltration and persistence. This review is of a study by sun. et al "Dendritic cell/tumor fusion cell vaccine combined with EGFRvIII-specific nanobody CAR T cells enhances antitumor efficacy against glioblastoma."; this study uses nanobody-based CAR T cells (Nb-CAR Ts), that camelid-derived single-domain antibodies to reduce steric hindrance, which has been shown to improve tumor penetration when compared to traditional CAR receptors. They used EGFRvIII-specific Nb-CAR Ts along with a dendritic cell/tumor fusion cell (FC) to target glioblastoma. EGFRvIII Nb-CAR Ts demonstrated enhanced proliferation, activation, cytokine production, and antigen-specific cytotoxicity in vitro. Key tests showed the effectiveness of the NB CarT cell alone when compared to control groups-- both in vivo and in vitro. NB CarT cell + FC had improved outcomes, both in vivo and in vitro when compared to NB CarT cell alone, FC alone, or NB CarT cell with non fusion dendritic cell. This study shows a promsing method of treating solid state tumors.
Referencias
1. Gross G, Eshhar Z. Endowing T cells with antibody specificity using chimeric T cell receptors. Nature. 1989;339(6225):70-72.
2. June CH, Sadelain M. Chimeric Antigen Receptor Therapy. N Engl J Med. 2018;379(1):64-
3. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both-primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161(6):2791-2797.
4. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676-684.
5. Chmielewski M, Abken H. CAR T cells releasing IL-12 convert the suppressive tumor microenvironment of pancreatic cancer into a highly inflammatory milieu. Cancer Immunol Immunother. 2012;61(4):653-662.
6. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
7. Newick K, O'Brien S, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139-152.
8. Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavychain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603.
9. Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J. R., & Ploegh, H. L. (2022). Nanobody-based CAR-T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy, 7(1), 36.
10. Xie YJ, Dougan M, Ingram JR, Pishesha N, Fry TJ, Mahmood U, et al. Improved antitumor efficacy of chimeric antigen receptor T cells derived from camelid single-domain antibodies. Cancer Immunol Res. 2019;7(7):1266-1273.
11. Li T, Qi S, Unger M, Hou Y, Deng Q, Liu J, et al. Suppression of tumor escape by targeting TGF-β signaling in CAR-T cell therapy. Mol Ther. 2020;28(11):2302-2312.
12. Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015;75(17):3596-3607.
13. Sun Y, Zhang C, Wang Z, Song J, Wang Y, Wang Z, et al. Dendritic cell/tumor fusion cell vaccine combined with EGFRvIII-specific nanobody CAR T cells enhances antitumor efficacy against glioblastoma. Cancer Immunol Immunother. 2023;72(2):345-359.
14. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462- 1466.
15. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280(21):5350-5370.
16. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008;20(5):267-275.
17. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39(1):38-48.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Yusef Elghzali
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
© The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license.
